If you are living with Diabetic Nephropathy or other forms of Chronic Kidney Disease you may qualify to join a novel clinical trial.
AION Healthspan, Inc. is conducting a clinical trial at the University of Miami Health System to evaluate the safety of REJUVXL, a novel cell therapy given through a simple IV infusion (similar to a blood transfusion) that does not require any anti-rejection drug. The objective of the clinical trial is to slow down, or possibly even reverse, Chronic Kidney Disease (CKD; Stage 3), with the goal of preventing progression to dialysis and kidney transplantation.
Why This Study Matters
- Chronic Kidney Disease affects hundreds of millions
- 1 in 3 adults with diabetes develops CKD
- Nearly 40% of people over 65 are affected
- Current treatments can only slow CKD progression towards dialysis and kidney transplantation
What is REJUVXL?
REJUVXL is an innovative cell therapeutic strategy developed to:
- Reduce inflammation in the kidneys
- Repair and regenerate damaged tissue
- Improve kidney function
- Slow or stop CKD progression
Who Can Participate?
You may qualify if you:
- Have been diagnosed with Stage 3 Chronic Kidney Disease
Participants will receive:
- Study-related medical care
- Close monitoring by leading kidney specialists
- A stipend will be provided for transportation costs and meals, to attend each onsite visit
- An opportunity to help advance CKD treatment for the future
Meet the Experts Leading the Study
University of Miami Nephrologist, Dr. Yelena Drexler, Principal Investigator of the study stated “current treatments for CKD are limited. If successful, REJUVXL could address the root causes of kidney disease, offering new hope to millions.” Dr. Alessia Fornoni, Leading Nephrologist at the University of Miami and member of the Scientific Advisory Board of AION Healthspan stated “this therapy could fill a critical gap in CKD treatment, providing a new option to protect and restore kidney function.”
Interested in Participating?
- Find out if you qualify today!
- Contact: Dr. Danay Saavedra Hernandez
- Email: dxs4415@med.miami.edu
- Tel: (305) 243-6616
Sign up for news to stay up to date on our clinical trial plans